<DOC>
	<DOCNO>NCT01999738</DOCNO>
	<brief_summary>Phase 1A/B , multicenter , open-label , non-randomized , dose-escalation oncology study evaluate administration EC1456 advance solid tumor . In part A , EC1456 dose escalate 4 concurrently enrol schedule . FR-positive expression 99mTc-etarfolatide scan require inclusion Part A . Part B study confirm maximum tolerate dose ( MTD ) recommend Phase 2 ( RP2 ) dose EC1456 , evaluate efficacy EC1456 NSCLC subtype patient population FR-positive cancer three schedule ( i.e. , twice weekly , weekly , four time weekly ) . FR-positive expression 99mTc-etarfolatide scan require inclusion Part B . Minimum length patient participation anticipate 10 week ( two 3-week cycle follow 30 day follow-up period ) .</brief_summary>
	<brief_title>Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>In part A , EC1456 dose escalate 4 concurrently enrol schedule . Treatment 1 EC1456 BIW Days 1 , 4 , 8 , 11 3-week schedule ( BIW ) ; Treatment 2 EC1456 QW Days 1 8 3-week schedule ( QW ) ; Treatment 3 EC1456 QW Days 1 , 8 , 15 3-week schedule ( CWD ) Treatment 4 EC1456 QIW Days 1 , 2 , 3 , 4 , 8 , 9 , 10 , 11 3-week schedule ( QIW ) . In part B , EC1456 dose 3 concurrently enrol schedule : Treatment 5 EC1456 BIW . Once dose determine Part A , Part B begin 3-6 subject receive consecutive day dose Days 1 , 2 , 8 , 9 3-week schedule . If tolerate , BIW cohort continue dose Days 1 , 4 , 8 , 11 3-week schedule ; Treatment 6 EC1456 QW Days 1 8 3-week schedule CWD Days 1 , 8 15 3-week schedule ; Treatment 7 EC1456 QIW Days 1 , 2 , 3 , 4 , 8 , 9 , 10 , 11 3-week schedule least two cycle . If patient eligible continue treatment ( base upon treatment response tolerability ) , he/she may opt continue QIW schedule change Treatment 6 regimen schedule ( MTD schedule determine ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Patients enrol Part A must receive 99mTc etarfolatide scan need FRpositive target lesion . Parts A B : To qualify enrollment , follow criterion must meet : 1 . Patient must ability understand sign approve informed consent form ( ICF ) . 2 . Patient must ≥ 18 year age . 3 . Patient must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 4 . Patient must life expectancy &gt; 3 month . 5 . Patient must least one measurable lesion per RECIST v1.1 Criteria assess baseline radiologic evaluation obtain 28 day prior begin study therapy . 6 . Patients central nervous system ( CNS ) metastases symptomatic must receive therapy ( e.g. , surgery , XRT , gamma knife , etc . ) neurologically stable steroid . The patient steroid least 14 day registration . Patients asymptomatic CNS metastatic disease without associate edema , shift , requirement steroid antiseizure medication may eligible discussion sponsor medical monitor . 7 . Patients must formalin fixed tissue ( biopsy FNA ) available . 8 . Patient must recover ( baseline/stabilization ) prior chemo radio therapy associate acute toxicity must resolve NCI CTCAE V4 Grade 1 less , exception alopecia . 9 . Patients treat prior radiation therapy may eligible : 1 . Radiotherapy complete least 2 week first dose EC1456 2 . Patient recover acute radiation toxicity . 10 . Patients must adequate organ function : 1 . Bone marrow reserve : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L ; Platelets ≥ 100 x 109/L ; Hemoglobin ≥ 9 g/dL . 2 . Cardiac : i. QTcFridericia ( QTcF ) &lt; 450 msec least 2 3 screen ECG 's . On site determination QTcF may use screen purpose . ii . Left ventricular ejection fraction ( LVEF ) equal great institutional low limit normal . LVEF must evaluate within 28 day prior C1D1 . iii . Cardiac Troponin I T within normal limit . ( whichever troponin do screen need do throughout rest study ) . c. Hepatic : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤ 3.0 x ULN OR ≤ 5.0 x ULN patient liver metastasis . d. Renal : Serum creatinine ≤ 1.5 x ULN patient serum creatinine &gt; 1.5 ULN , creatinine clearance ≥ 50 mL/min . Patients childbearing potential : 11 . All woman childbearing potential MUST negative urine serum pregnancy test within 1 week prior 99mTcetarfolatide imaging procedure within 1 week prior treatment EC1456 . 12 . Women child bear potential must practice effective method birth control ( i.e. , oral , transdermal injectable contraceptive , intrauterine device [ IUD ] , doublebarrier contraception , diaphragm spermicidal jelly ) duration participation trial 90 day follow last dose EC1456 . 13 . Male patient sexually active must practice effective method birth control ( e.g. , condom spermicidal jelly ) duration participation trial 90 day follow last dose EC1456 . Patient Disease Specific Part A EC1456 dose escalation cohort ( Treatments 1 , 2 , 3 , 4 ) : 14 . Patients must pathologically confirm metastatic locally advanced solid cancer ( preferably TNBC , NSCLC , ovarian , endometrial cancer due frequent high FR expression cancer ) fail respond standard therapy , amenable standard therapy , standard therapy exist . 15 . TNBC ovarian patient must agree submit result BRCA 1/2 status ( i.e. , deleterious mutation present , mutation unknown significance , mutation detect ) know . BRCA test require study inclusion . 16 . Patients must receive ≤ 4 prior line systemic anticancer therapy ( include limit cytotoxic agent , target inhibitor , monoclonal antibody ) . Hormonal therapy include toward criterion . 17 . Patients must undergo 99mTcetarfolatide SPECT image procedure compliance Investigator 's Imaging Operations Manual ( IIOM ) . FR expression 99mTc etarfolatide SPECT require inclusion Treatments 1 , 2 , 3 , 4 . ( Patients underwent 99mTcetarfolatide SPECT/CT imaging procedure subject Endocyte study EC20.12 require repeat scan participation study EC145601 scan obtain within 4 week cycle 1 day 1 EC1456 administration deem acceptable Endocyte Imaging . ) Part B Only : Patient Disease Specific Part B Patients FRpositive NSCLC ( subtypes ) : ( Treatments 5 , 6 , 7 ) 18 . Patients NSCLC ( subtypes ) must receive one prior platinum base therapy advance metastatic disease . No additional cytotoxic therapy advance metastatic disease allow . Any number prior targeted therapy ( e.g. , inhibitor ALK , EGFR , PD1 PDL1 ) allow . Patients know relevant genomic tumor aberration ( i.e. , EGFR , ALK , ROS1 , etc ) must receive progressed approve therapy aberration . This information must document prior study entry . 19 . Patients must undergo 99mTcetarfolatide SPECT image procedure compliance Investigator 's Imaging Operations Manual ( IIOM ) FRpositive . Parts A B : The presence follow exclude patient study : 1 . Systemic anticancer treatment , except hormonal treatment , within 28 day prior EC1456 administration unless remain ongoing uncontrolled toxicity . Please contact medical monitor discus request less 28 day washout period . 2 . Known hypersensitivity component study therapy analog . 3 . Carcinomatous meningitis and/or symptomatic central nervous system ( CNS ) metastases . 4 . Malignancies expect alter life expectancy may interfere disease assessment . Patients adequately treat nonmelanoma skin cancer , carcinoma situ cervix , lowgrade ( Gleason score ≤ 6 ) localize prostate cancer , ductal carcinoma situ ( DCIS ) , patient prior history malignancy disease free 3 year eligible . 5 . Serious cardiac illness medical condition unstable angina , pulmonary embolism , uncontrolled hypertension . 6 . Patients consider risk lifethreatening QTc prolongation ( i.e. , personal family history Long QT syndrome , presence implantable pacemaker implantable cardioverter defibrillator , etc. ) . 7 . Use following medication within 6 month prior EC1456 administration : amiodarone , disopyramide , dofetilide , dronedarone , flecanamide , ibutilide , quinidine , sotalol . 8 . Need concurrent antifolate therapy methotrexate rheumatoid arthritis . 9 . Other concurrent chemotherapy , immunotherapy , radiotherapy , investigational therapy . 10 . Pregnant lactating woman . 11 . Active uncontrolled infection . 12 . Known active Hepatitis B C infection . 13 . Unable unwilling pretreatment scan perform 99mTcetarfolatide reason ( claustrophobia , inability lie supine image table pain cardiopulmonary disease , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>